Comparative Pharmacology
Head-to-head clinical analysis: LEGUBETI versus WILPO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEGUBETI versus WILPO.
LEGUBETI vs WILPO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Legubeti is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin secretion.
Wilpo (setmelanotide) is a melanocortin 4 receptor (MC4R) agonist that activates the MC4R pathway to reduce appetite and increase energy expenditure.
500 mg orally twice daily
WILPO is not a known or approved drug. No standard dosing information available.
None Documented
None Documented
Terminal half-life: 12 hours; steady-state reached after 2-3 days; adjust dose in renal impairment
Terminal elimination half-life of 12 hours (range 10-14 h). Steady-state achieved after 2-3 days. Requires dose adjustment in renal impairment (CrCl <30 mL/min).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Primarily renal (unchanged: 60%, glucuronide conjugate: 20%), biliary/fecal: 15%, other: 5%.
Category C
Category C
Unknown
Unknown